Morgan Stanley analyst Sean Laaman assumed coverage of Halozyme (HALO) with an Overweight rating and $67 price target Halozyme has a diversified revenue stream as it extracts royalties from multi-company products of generally high growth, says the analsyt, who forecasts the company delivering revenue and EPS compound annual growth rates of 23% and 25%, respectively, for 2023-2028.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Board Member Connie Matsui Steps Down
- Halozyme’s Strategic Advancements and Market Potential Justify Buy Rating
- Positive Regulatory Developments and Revenue Growth Potential Support Buy Rating for Halozyme Therapeutics
- Halozyme announces positive opinion in EU for rybrevant with Enhanze technology
- Halozyme price target lowered to $57 from $62 at Wells Fargo